In conclusion, our study established the clinical, PD and translational rationale to select a late-stage molecule to target one of the most prevalent mutations in LGGs and provides a rich data resource to advance our understanding of the role of IDH mutations and the mechanism of action of IDH inhibitors in recurrent gliomas. This evidence concerns the gene IDH1 and glioma.